116 related articles for article (PubMed ID: 25677789)
1. Targeting FGF19 binding to its receptor system: a novel therapeutic approach for hepatocellular carcinoma.
Panera N; Ceccarelli S; Nobili V; Alisi A
Hepatology; 2015 Oct; 62(4):1324. PubMed ID: 25677789
[No Abstract] [Full Text] [Related]
2. Reply: To PMID 24798001.
Haq F; Ahn SM
Hepatology; 2015 Oct; 62(4):1324-5. PubMed ID: 25677638
[No Abstract] [Full Text] [Related]
3. New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment.
Vilarinho S; Calvisi DF
Hepatology; 2014 Dec; 60(6):1812-4. PubMed ID: 25042754
[No Abstract] [Full Text] [Related]
4. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
Ahn SM; Jang SJ; Shim JH; Kim D; Hong SM; Sung CO; Baek D; Haq F; Ansari AA; Lee SY; Chun SM; Choi S; Choi HJ; Kim J; Kim S; Hwang S; Lee YJ; Lee JE; Jung WR; Jang HY; Yang E; Sung WK; Lee NP; Mao M; Lee C; Zucman-Rossi J; Yu E; Lee HC; Kong G
Hepatology; 2014 Dec; 60(6):1972-82. PubMed ID: 24798001
[TBL] [Abstract][Full Text] [Related]
5. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.
Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y
Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355
[TBL] [Abstract][Full Text] [Related]
6. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling.
Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C
Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455
[TBL] [Abstract][Full Text] [Related]
7. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
[TBL] [Abstract][Full Text] [Related]
8. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Kaibori M; Sakai K; Ishizaki M; Matsushima H; De Velasco MA; Matsui K; Iida H; Kitade H; Kwon AH; Nagano H; Wada H; Haji S; Tsukamoto T; Kanazawa A; Takeda Y; Takemura S; Kubo S; Nishio K
Oncotarget; 2016 Aug; 7(31):49091-49098. PubMed ID: 27384874
[TBL] [Abstract][Full Text] [Related]
9. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
Desnoyers LR; Pai R; Ferrando RE; Hötzel K; Le T; Ross J; Carano R; D'Souza A; Qing J; Mohtashemi I; Ashkenazi A; French DM
Oncogene; 2008 Jan; 27(1):85-97. PubMed ID: 17599042
[TBL] [Abstract][Full Text] [Related]
10. Editing liver tumours.
Colnot S; Fortes P
Gut; 2014 May; 63(5):709-10. PubMed ID: 23878166
[No Abstract] [Full Text] [Related]
11. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
Li Y; Zhang W; Doughtie A; Cui G; Li X; Pandit H; Yang Y; Li S; Martin R
Oncotarget; 2016 Aug; 7(32):52329-52339. PubMed ID: 27447573
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed by miR-139.
Yang L; Yin D; Wang Y; Cao L
Oncol Rep; 2017 Oct; 38(4):2565-2571. PubMed ID: 28765917
[TBL] [Abstract][Full Text] [Related]
13. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
[TBL] [Abstract][Full Text] [Related]
14. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
Liu WY; Xie DM; Zhu GQ; Huang GQ; Lin YQ; Wang LR; Shi KQ; Hu B; Braddock M; Chen YP; Zheng MH
Expert Opin Ther Targets; 2015 May; 19(5):675-85. PubMed ID: 25547779
[TBL] [Abstract][Full Text] [Related]
15. Liver cancer: A model of fibrolamellar carcinoma.
Patman G
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):672. PubMed ID: 26503883
[No Abstract] [Full Text] [Related]
16. The Spectrum of E2F in Liver Disease--Mediated Regulation in Biology and Cancer.
Huntington JT; Tang X; Kent LN; Schmidt CR; Leone G
J Cell Physiol; 2016 Jul; 231(7):1438-49. PubMed ID: 26566968
[TBL] [Abstract][Full Text] [Related]
17. [Tumor suppressor RB gene and its related molecules in hepatocellular carcinoma].
Nishida N; Fukuda Y
Nihon Rinsho; 2001 Oct; 59 Suppl 6():134-7. PubMed ID: 11761929
[No Abstract] [Full Text] [Related]
18. Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing.
Lin KT; Shann YJ; Chau GY; Hsu CN; Huang CY
Oncogene; 2014 Sep; 33(39):4786-94. PubMed ID: 24141781
[TBL] [Abstract][Full Text] [Related]
19. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
20. miR-675 mediates downregulation of Twist1 and Rb in AFP-secreting hepatocellular carcinoma.
Hernandez JM; Elahi A; Clark CW; Wang J; Humphries LA; Centeno B; Bloom G; Fuchs BC; Yeatman T; Shibata D
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S625-35. PubMed ID: 23864307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
